We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Oxford BioDynamics
Commercialising cutting edge diagnosticsScancell
SCOPE readouts in sight; SCIB1 data in Q424ANGLE
H124: renewed near-term focus on Pharma ServicesAvacta
H124 interims: a time to reflect on progress achievedArecor Therapeutics
H124: Focus on next steps for diabetes and obesityHUTCHMED
Flow of catalysts continues, with more into 2025Scancell
FY24: Cash to deliver on key clinical catalystsAvacta
ESMO 24: compelling data for AVA6000 and pre|CISIONArecor Therapeutics
EASD 2024: Positive Phase I for AT278 in Type II diabetesFutura Medical
Earlier US Eroxon launch brings forward profitability